QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=2F2A3216137F3E590CE727FF0B4C92D2;jsessionid=83FB169AC20A50822260F9974618FB02;jsessionid=00A77FF45DE8089BE4B95E95CDD70E56;jsessionid=8F02459A0647DEC8EB5B304DFEAAA0DC;jsessionid=199B66188E44D3394CF487E03A90B0FB;jsessionid=FD45B962B21D6C5BA1A30036520D01AE;jsessionid=B0D8A49A84A16FEFDB21A417CED38D51;jsessionid=E566123C92729E9F4C83D6B029A951CF;jsessionid=9046B72A0244DC464EA12D1FD9264703;jsessionid=5295FB418A3D95CD771A3F6725888CAC (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=2F2A3216137F3E590CE727FF0B4C92D2;jsessionid=83FB169AC20A50822260F9974618FB02;jsessionid=00A77FF45DE8089BE4B95E95CDD70E56;jsessionid=8F02459A0647DEC8EB5B304DFEAAA0DC;jsessionid=199B66188E44D3394CF487E03A90B0FB;jsessionid=FD45B962B21D6C5BA1A30036520D01AE;jsessionid=B0D8A49A84A16FEFDB21A417CED38D51;jsessionid=E566123C92729E9F4C83D6B029A951CF;jsessionid=9046B72A0244DC464EA12D1FD9264703;jsessionid=5295FB418A3D95CD771A3F6725888CAC